오소바이오로직스 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 용도별, 최종 용도별, 지역별, 부문별 예측(2024-2030년)

Orthobiologics Market Growth & Trends:

The global orthobiologics market size is expected to reach USD 9.3 billion by 2030, registering a CAGR of 5.5% from 2024 to 2030, according to a new report by Grand View Research, Inc. Increasing cases of orthopedic surgeries across the globe is driving the demand for orthobiologics. A study presented at the Annual Meeting of the American Academy of Orthopedic Surgeons (AAOS) 2023, revealed that orthopedic surgeons would face a challenge in meeting the increasing demand for total joint arthroplasty (TJA). The study found that to keep up with the demand, surgeons will have to either double their TJA caseload or increase the number of surgeons by 10% every five years.

With an increasing focus on healthcare advancements and patient outcomes, governments worldwide are implementing policies and initiatives to foster the growth of orthobiologics. For instance, the American Academy of Orthopedic Surgeons (AAOS) is committed to improving musculoskeletal care in a transparent and scientific way. In October 2020, the AAOS launched the Biologics Dashboard on their website, which is designed to assist orthopedic surgeons in keeping track of the approval status of biologic-based interventions. This initiative is a part of the AAOS Biologics Initiative, which offers evidence-based guidance to the musculoskeletal health community. As part of this effort, the AAOS Board of Directors also revised two position statements related to biologics.

Increasing geriatric population across the globe is also anticipated to boost the demand for orthopedic surgeries. According to the India Ageing Report 2023, country's elderly population is growing at a rapid pace, with a decadal growth rate of 41%. By 2050, over 20% of India's population will be elderly citizens.As people age, they are more likely to experience issues with their muscles and bones, such as osteoporosis, osteoarthritis, and fractures. This results in a greater need for orthobiologics solutions.

Moreover, increasing cases of road accidents is anticipated to supplement the market growth. According to the National Highway Traffic Safety Administration report, there were an estimated 19,515 deaths in motor vehicle accidents during the first half of 2023. This represents a decrease of about 3.3% compared to the same period in the previous year, which had 20,190 fatalities. The report also shows that fatalities decreased during both the first and second quarters of 2023. Thus, the increasing number of injured populations is expected to increase the demand for orthobiologics.

The major players operating in the market are adopting strategies such as collaborations, supply agreements, and partnerships with a major focus on enhancing the product formation and reach. For instance, inSeptember 2023, HippoFi Inc. partnered with Zimmer Biomet Holdings Inc. to bring forth a synthetic biomaterial for bone growth. The biomaterial will be launched under HippoFi's biologic subsidiary, PUR Biologics in 2024.

Orthobiologics Market Report Highlights:

• Based on product, the viscosupplementation segment held the largest revenue share in the market in 2023 owing to the increasing prevalence of lifestyle-related conditions and advances in hyaluronic acid therapy development
• Based on application, the spinal fusion segment held the largest revenue share in the market in 2023 owing to the rising incidence of degenerative disc disease
• Based on end-use, the hospitals segment accounted for the largest revenue share due to the growing patient population undergoing surgical procedures
• North America dominated the market due to the presence of several market players and a well-established regulatory framework

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Segment scope
  • 1.1.2. Regional scope
  • 1.1.3. Estimates and forecast timeline
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity flow analysis (Model 1)
    • 1.6.1.1. Approach 1: Commodity flow approach
• 1.7. Research Assumptions
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
  • 2.2.2. Application outlook
  • 2.2.3. End-use outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Global Orthobiologics Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
• 3.3. Orthobiologics: Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTLE Analysis
• 3.4. Regulatory Framework

Chapter 4. Global Orthobiologics Market Segment Analysis, By Product, 2018 - 2030 (USD Billion)

• 4.1. Definition and Scope
• 4.2. Product Type Market Share Analysis, 2023 & 2030
• 4.3. Segment Dashboard
• 4.4. Global Orthobiologics Market, by Product Type, 2018 to 2030
• 4.5. Demineralized Bone Matrix (DBM)
  • 4.5.1. Demineralized Bone Matrix (DBM) market estimates and forecasts, 2018 to 2030 (USD Billion)
• 4.6. Allograft
  • 4.6.1. Allograft market estimates and forecasts, 2018 to 2030 (USD Billion)
• 4.7. Bone morphogenetic protein (BMP)
  • 4.7.1. Bone morphogenetic protein (BMP) market estimates and forecasts, 2018 to 2030 (USD Billion)
• 4.8. Viscosupplementation
  • 4.8.1. Viscosupplementation market estimates and forecasts, 2018 to 2030 (USD Billion)
• 4.9. Synthetic bone substitutes
  • 4.9.1. Synthetic bone substitutes market estimates and forecasts, 2018 to 2030 (USD Billion)
• 4.10. Stem cell therapy
  • 4.10.1. Stem cell therapy market estimates and forecasts, 2018 to 2030 (USD Billion)

Chapter 5. Global Orthobiologics Market Segment Analysis, By Application, 2018 - 2030 (USD Billion)

• 5.1. Definition and Scope
• 5.2. Application Market Share Analysis, 2023 & 2030
• 5.3. Segment Dashboard
• 5.4. Global orthobiologics Market, by Application, 2018 to 2030
• 5.5. Spinal Fusion
  • 5.5.1. Spinal fusion market estimates and forecasts, 2018 to 2030 (USD Billion)
• 5.6. Trauma repair
  • 5.6.1. Trauma repair market estimates and forecasts, 2018 to 2030 (USD Billion)
• 5.7. Reconstructive surgery
  • 5.7.1. Reconstructive surgery market estimates and forecasts, 2018 to 2030 (USD Billion)

Chapter 6. Global Orthobiologics Market Segment Analysis, By End-use, 2018 - 2030 (USD Billion)

• 6.1. Definition and Scope
• 6.2. End-use Market Share Analysis, 2023 & 2030
• 6.3. Segment Dashboard
• 6.4. Global Orthobiologics Market, by end-use, 2018 to 2030
• 6.5. Hospitals
  • 6.5.1. Hospitals market estimates and forecasts, 2018 to 2030 (USD Billion)
• 6.6. Outpatient facilities
  • 6.6.1. Outpatient facilities market estimates and forecasts, 2018 to 2030 (USD Billion)

Chapter 7. Global Orthobiologics Market Segment Analysis, By Region, 2018 - 2030 (USD Billion)

• 7.1. Regional Market Share Analysis, 2023 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Regional Market Snapshot
• 7.4. Orthobiologics Market Share by Region, 2023 & 2030
• 7.5. North America
  • 7.5.1. North America orthobiologics market, 2018 - 2030 (USD Billion)
  • 7.5.2. U.S.
    • 7.5.2.1. U.S. orthobiologics market, 2018 - 2030 (USD Billion)
  • 7.5.3. Canada
    • 7.5.3.1. Canada orthobiologics market, 2018 - 2030 (USD Billion)
• 7.6. Europe
  • 7.6.1. Europe orthobiologics market, 2018 - 2030 (USD Billion)
  • 7.6.2. UK
    • 7.6.2.1. UK orthobiologics market, 2018 - 2030 (USD Billion)
  • 7.6.3. Germany
    • 7.6.3.1. Germany orthobiologics market, 2018 - 2030 (USD Billion)
  • 7.6.4. France
    • 7.6.4.1. France orthobiologics market, 2018 - 2030 (USD Billion)
  • 7.6.5. Italy
    • 7.6.5.1. Italy orthobiologics market, 2018 - 2030 (USD Billion)
  • 7.6.6. Spain
    • 7.6.6.1. Spain orthobiologics market, 2018 - 2030 (USD Billion)
  • 7.6.7. Norway
    • 7.6.7.1. Norway orthobiologics market, 2018 - 2030 (USD Billion)
  • 7.6.8. Sweden
    • 7.6.8.1. Sweden orthobiologics market, 2018 - 2030 (USD Billion)
  • 7.6.9. Denmark
    • 7.6.9.1. Denmark orthobiologics market, 2018 - 2030 (USD Billion)
• 7.7. Asia Pacific
  • 7.7.1. Japan
    • 7.7.1.1. Japan orthobiologics market, 2018 - 2030 (USD Billion)
  • 7.7.2. China
    • 7.7.2.1. China orthobiologics market, 2018 - 2030 (USD Billion)
  • 7.7.3. India
    • 7.7.3.1. India orthobiologics market, 2018 - 2030 (USD Billion)
  • 7.7.4. Australia
    • 7.7.4.1. Australia orthobiologics market, 2018 - 2030 (USD Billion)
  • 7.7.5. South Korea
    • 7.7.5.1. South Korea orthobiologics market, 2018 - 2030 (USD Billion)
  • 7.7.6. Thailand
    • 7.7.6.1. Thailand orthobiologics market, 2018 - 2030 (USD Billion)
• 7.8. Latin America
  • 7.8.1. Brazil
    • 7.8.1.1. Brazil orthobiologics market, 2018 - 2030 (USD Billion)
  • 7.8.2. Mexico
    • 7.8.2.1. Mexico orthobiologics market, 2018 - 2030 (USD Billion)
  • 7.8.3. Argentina
    • 7.8.3.1. Argentina orthobiologics market, 2018 - 2030 (USD Billion)
• 7.9. MEA
  • 7.9.1. South Africa
    • 7.9.1.1. South Africa orthobiologics market, 2018 - 2030 (USD Billion)
  • 7.9.2. Saudi Arabia
    • 7.9.2.1. Saudi Arabia orthobiologics market, 2018 - 2030 (USD Billion)
  • 7.9.3. UAE
    • 7.9.3.1. UAE orthobiologics market, 2018 - 2030 (USD Billion)
  • 7.9.4. Kuwait
    • 7.9.4.1. Kuwait orthobiologics market, 2018 - 2030 (USD Billion)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company Categorization
• 8.3. Company Profiles
  • 8.3.1. Medtronic Plc
    • 8.3.1.1. Company overview
    • 8.3.1.2. Financial performance
    • 8.3.1.3. Product benchmarking
    • 8.3.1.4. Strategic initiatives
  • 8.3.2. DePuy Synthes
    • 8.3.2.1. Company overview
    • 8.3.2.2. Financial performance
    • 8.3.2.3. Product benchmarking
    • 8.3.2.4. Strategic initiatives
  • 8.3.3. Zimmer Biomet
    • 8.3.3.1. Company overview
    • 8.3.3.2. Financial performance
    • 8.3.3.3. Product benchmarking
    • 8.3.3.4. Strategic initiatives
  • 8.3.4. Stryker Corporation
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. Bioventus LLC
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Product benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Seaspine Holdings Corporation
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Product benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Orthofix, Inc.
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Product benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Globus Medical
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Product benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Arthrex, Inc.
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Product benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. Bone Biologics Corp.
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Product benchmarking
    • 8.3.10.4. Strategic initiatives